} .hero h1{ color: $lt-green; font-weight: 400; font-size: 10px; @media (max-width: 991px) { font-size: 10px; font-weight: 500; } } EIP Pharma: treating neurodegenerative diseases

We believe the key to treating neurodegenerative disease is to intervene early.

Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking. Their ability to go about their daily lives is impacted by these progressive conditions. We believe that by applying our approach we can reverse the synaptic dysfunction that, ahead of death of nerve cells, is responsible for disease symptoms and progression.

Our Approach

A FOCUS ON

Neurodegenerative Disease

Dementia with Lewy Bodies

Patients with this disease accumulate protein deposits, called Lewy bodies, in the brain’s nerve cells. This negatively affects both cognitive ability - including attention, judgement, and reasoning – and motor function.

Alzheimer’s Disease

Alzheimer’s disease is a condition characterized by memory loss, disorientation and other cognitive deficits that worsen as the disease progresses.

Stroke Recovery

Stroke, caused by blockage of arteries supplying blood to the brain, is the number one cause of long-term disability in adults. Most stroke survivors have some level of recovery after a stroke. However, in moderately severe and severe stroke the recovery is often incomplete.

 EIP Pharma's Approach for Dementia with Lewy Bodies

     

Hope Through Science

Introducing Neflamapimod

We’re developing neflamapimod—an oral, selective small molecule inhibitor of the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, the reversible aspect of the neurodegenerative process. The preclinical data with neflamapimod, along with evidence from recent phase 2 clinical studies in dementia with Lewy bodies (DLB) and in Alzheimer’s disease (AD), strongly suggest that inhibition of p38 alpha by neflamapimod reverses the synaptic dysfunction that underlies disease progression in the early stages of many neurological disorders.

Treatment & Results

EIP Pharma in the News

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma’s neflamapimod in dementia with Lewy bodies

January 18, 2023

Presentation of MRI data at Clinical Trials and Alzheimer’s Disease (CTAD) conference demonstrates potential of neflamapimod to positively impact the cholinergic degenerative process in early Alzheimer’s disease (AD)

December 2, 2022

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

September 21, 2022


News & Events